Sickle cell therapeutic treatment

• US 4,216,770 A
• Filed: 02/09/1979
• Issued: 08/12/1980
• Est. Priority Date: 02/09/1979
• Status: Expired due to Term

• Current Assignee: Baxter Travenol Laboratories Incorporated (Baxter International Inc.)
• Original Assignee: Baxter Travenol Laboratories Incorporated (Baxter International Inc.)
• Inventors: Cullis, Herbert M., Dorsey, Evelyn E.
• Primary Examiner(s): Kamm, William E.
• Assistant Examiner(s): Wallen, Thomas J.
• Application Number:
  US06/010,941
• Time in Patent Office: 550 Days
• Field of Search: 128/214 R, 233/1 R, 210/DIG. 23, 210/22, 210/23
• US Class Current: 604/6.02
• CPC Class Codes: A61M 1/3687 Chemical treatment A61M1/3675 takes precedence
• CPC Class Codes: A61M 1/3692 Washing or rinsing blood or blood constituents
• CPC Class Codes: A61M 1/3693 using separation based on different densities of components, e.g. centrifuging
• CPC Class Codes: A61M 1/3696 with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
• CPC Class Codes: A61M 2202/0429 Red blood cells; Erythrocytes
• CPC Class Codes: B04B 2005/0471 with additional elutriation separation of different particles

Abstract

A sickle cell therapeutic treatment is provided by means of continuous flow red blood cell carbamylation. In a substantially continuous process, whole blood is removed from a patient and is directed to a red cell separator chamber of a seal-less type centrifuge. The whole blood is centrifuged and the red blood cells to be treated are removed from the red cell separation chamber and are directed to a reaction chamber. An anti-sickle agent, such as cyanate solution, is introduced into the reaction chamber and is mixed with the red blood cells to be treated. The mixed anti-sickle agent and red blood cells are transferred to a wash chamber in the centrifuge where they are washed, by centrifugation, and the washed, treated red blood cells are combined with the plasma that was separated in the red cell separation chamber and the combination is returned to the patient.

Claims

1. A process for treating sickle cell disease including the step of withdrawing whole blood substantially continuously from a patient and during said withdrawal of said whole blood performing the following steps:

directing the whole blood to a red cell separator;

separating red blood cells to be treated from said plasma by centrifugation;

directing the centrifuged separated red blood cells to be treated to a reaction chamber;

introducing an anti-sickle agent into said reaction chamber and mixing the anti-sickle agent with the red blood cells to be treated;

directing red blood cells mixed with the anti-sickle agent to a wash chamber;

introducing washing medium into the wash chamber and washing by centrifugation the red blood cells mixed with the anti-sickle agent;

removing the washed red blood cells from the centrifuge and directing the washed, treated red blood cells back to the patient.

2. A process as described in claim 1, including the step of separating the plasma from the red blood cells to be treated and directing the plasma back to the patient.

3. A process as described in claim 2, including the step of mixing the plasma directed back to the patient with the washed, treated red blood cells.

4. A process as described in claim 1, including the step of separating said red blood cells to be treated from the white cells and platelets.

5. A process as described in claim 1, including the step of removing waste from the reaction chamber and the wash chamber.

6. A process as described in claim 1, including the step of introducing an anti-coagulant to the whole blood before the blood cells to be treated are separated from the plasma.

7. A process as described in claim 1, including the step of directing to the reaction chamber substantially only cells that are free of granulocytes, lymphocytes, reticulocytes and platelets.

8. A process for treating sickle cell disease including the step of withdrawing whole blood substantially continuously from a patient and during said withdrawal of said whole blood performing the following steps:

directing the whole blood to a red cell separator;

introducing an anti-coagulant to the whole blood;

separating red blood cells to be treated from said plasma by centrifugation;

directing the plasma back to the patient;

directing the centrifuged, separated red blood cells to be treated to a reaction chamber;

introducing an anti-sickle agent into said reaction chamber and mixing the anti-sickle agent with the red blood cells to be treated;

directing red blood cells mixed with the anti-sickle agent to a wash chamber;

introducing washing medium into the wash chamber and washing by centrifugation the red blood cells mixed with the anti-sickle agent;

removing the washed red blood cells from the centrifuge and directing the washed, treated red blood cells back to the patient;

removing waste from the reaction chamber and the wash chamber; and

mixing the plasma directed back to the patient with the washed, treated red blood cells directed back to the patient.

9. A process as described in claim 8, including the step of directing to the reaction chamber substantially only cells that are free of granulocytes, lymphocytes, reticulocytes and platelets.